OncoSil Medical Limited (ASX:OSL)

Market Cap	28.24M
Revenue (ttm)	1.54M
Net Income (ttm)	-15.10M
Shares Out	18.82M
EPS (ttm)	-1.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,431
Average Volume	11,592
Open	1.510
Previous Close	1.500
Day's Range	1.500 - 1.510
52-Week Range	0.800 - 4.400
Beta	1.18
RSI	41.22
Earnings Date	Nov 28, 2025

About OncoSil Medical

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: OSL

Financial Performance

In 2025, OncoSil Medical's revenue was 1.54 million, a decrease of -1.92% compared to the previous year's 1.57 million. Losses were -15.10 million, 26.7% more than in 2024.